Ecolab (ECL) Q3 2024 earnings summary

Executive summary

• Achieved strong Q3 2024 growth with reported sales of $4.0 billion, up 1% year-over-year despite a 2% headwind from the sale of the global surgical solutions business and 1% from currency exchange; organic sales grew 4%.

• Adjusted diluted EPS rose 19% to $1.83; reported diluted EPS was $2.58, up 83% due to a gain from the surgical solutions business sale.

• Reported operating income increased 85% year-over-year; organic operating income up 22%, driven by improved volume, value pricing, and lower delivered product costs.

• Raised full-year 2024 adjusted diluted EPS outlook to $6.60–$6.70, a 27–29% increase over 2023, reflecting strong momentum into 2025.

• Major gain from the sale of the global surgical solutions business contributed $365.3 million pre-tax.

Financial highlights

• Organic sales grew 4% year-over-year; Q3 2024 net sales were $3.99–$4.0 billion (+1%).

• Gross margin expanded 220–230 basis points to 43.4–43.5%.

• Operating income margin expanded 260 basis points to 17.9%; reported operating income margin reached 26.1%.

• Cash from operations for the nine months ended September 30, 2024, was $2.05 billion, up from $1.56 billion in 2023.

• Free cash flow increased 35% to $1.4 billion year-to-date.

Outlook and guidance

• Full-year 2024 adjusted diluted EPS expected in the $6.60–$6.70 range, up 27–29% from 2023, including an $0.08 per share headwind from the surgical solutions divestiture.

• Q4 2024 adjusted diluted EPS expected between $1.75–$1.85, up 13–19% year-over-year.

• 2025 and beyond: maintain 12–15% adjusted diluted EPS growth trajectory and target a 20% operating income margin within three years.

• One Ecolab initiative targets $175 million in restructuring costs and $225 million in annualized cost savings by 2027.

• Value pricing expected to remain in the 2–3% range for 2025.